Maprotiline Ratiopharm

Maprotiline, the active ingredient in Maprotiline Ratiopharm, is a tetracyclic antidepressant presented as an oral dosage form for oral use. It is prescribed for the treatment of depressive disorders in adult patients.

GNH USA supplies Maprotiline Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maprotiline is a tetracyclic antidepressant that acts on depressive disorders. - Major depressive disorder: reduction of depressive symptoms and improvement of mood. - Depressive episodes in bipolar disorder (adjunct therapy): alleviation of depressive phase symptoms. - Dysthymic disorder: long‑term improvement of persistent low mood.

Common side effects are usually mild to moderate and may resolve with continued therapy.

Common Side Effects: - Dry mouth: reduced salivation causing discomfort. - Drowsiness: increased sleepiness or fatigue. - Constipation: slowed gastrointestinal motility. - Weight gain: gradual increase in body weight. - Dizziness: sensation of light‑headedness. - Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects: - Seizures: risk of convulsive episodes. - Cardiac arrhythmia: irregular heart rhythm. - Severe hypotension: marked drop in blood pressure. - Hepatic dysfunction: abnormal liver enzyme elevations. - Agranulocytosis: dangerously low white blood cell count. - Suicidal thoughts: emergence or worsening of suicidal ideation.

Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks. - Cardiovascular assessment: monitor blood pressure and heart rhythm in patients with cardiac disease. - Discontinuation syndrome: avoid abrupt cessation; taper dose under medical supervision. - Elderly patients: start at lower doses and monitor for increased sensitivity. - Hepatic function: assess liver enzymes before and during treatment. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Maprotiline may interact with several drug classes; careful review of concomitant medications is essential.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Selective serotonin reuptake inhibitors (SSRIs): potential serotonin syndrome. - Other tricyclic antidepressants: additive cardiotoxicity. - CNS depressants (e.g., benzodiazepines): enhanced sedation. - Linezolid: increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: possible additive blood pressure lowering. - Anticholinergic drugs: heightened anticholinergic burden. - Alcohol: increased drowsiness and CNS depression. - CYP2D6 inhibitors: elevated maprotiline plasma levels. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased risk of gastrointestinal bleeding.